Daniel Brown retired from the partnership in December 2025. He was a seasoned first-chair patent trial lawyer, representing pharmaceutical and life sciences companies in patent litigation and other existential disputes, as well as advising on complex cross-disciplinary strategy.
Daniel leveraged his chemical engineering background and extensive pharmaceutical IP litigation experience to help clients navigate matters involving patent protection, Food and Drug Administration (FDA) regulation, antitrust and competition, inter partes reexamination proceedings, trade secrets, business and licensing transactions and disputes, due diligence, and investigations. He guided clients on:
- Pharmaceutical and life sciences litigation, trials, and appeals
- Hatch-Waxman Act cases
- Complex matters involving simultaneous patent, antitrust, and FDA litigation
- Patent litigation parallel with Patent Office re-issue, reexamination, and interference proceedings
- Coordinated litigation proceedings in multiple countries, including strategizing with local counsel
He delivered strategy and counseling from a business-focused perspective, coordinating FDA, litigation, and commercial strategy. Daniel connected clients to resources across Latham’s integrated global platform to maximize value, particularly across the FDA Regulatory, Antitrust & Competition, and Government Contracts practices.